ES2054772T3 - Anticuerpos monoclonales capaces de reconocer acido n-acetilneuraminico en configuracion beta. - Google Patents

Anticuerpos monoclonales capaces de reconocer acido n-acetilneuraminico en configuracion beta.

Info

Publication number
ES2054772T3
ES2054772T3 ES88118876T ES88118876T ES2054772T3 ES 2054772 T3 ES2054772 T3 ES 2054772T3 ES 88118876 T ES88118876 T ES 88118876T ES 88118876 T ES88118876 T ES 88118876T ES 2054772 T3 ES2054772 T3 ES 2054772T3
Authority
ES
Spain
Prior art keywords
acetylneuraminic acid
recognizing
monoclonal antibodies
antibodies capable
hybridoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88118876T
Other languages
English (en)
Inventor
Atsushi Kawamura
Isao Suda
Kinji Takada
Masayoshi Ito
Yoshiyasu Shitori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KANTO ISHI PHARMA CO Ltd
Mect Corp
Original Assignee
KANTO ISHI PHARMA CO Ltd
Mect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KANTO ISHI PHARMA CO Ltd, Mect Corp filed Critical KANTO ISHI PHARMA CO Ltd
Application granted granted Critical
Publication of ES2054772T3 publication Critical patent/ES2054772T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

UN HIBRIDOMA PRODUCIENDO UN ANTICUERPO MONOCLONAL ESPECIFICO PARA EL ACIDO N - ACETILNEURAMINICO O UN DERIVADO DE ESTE EN UN DISPOSITIVO BETA COMO UN EPITOPE DESCRITO. EL ANTICUERPO MONOCLONAL PRODUCIDO POR EL HIBRIDOMA PUEDE USARSE CON PROPOSITOS CLINICOS COMO SON EL DIAGNOSTICO Y PRONOSTICO DE CIERTOS TIPOS DE CANCER Y ENFERMEDADES INFLAMATORIAS AGUDAS. EL HIBRIDOMA SE PUEDE GENERAR POR FUSION (I) DE CELULAS B O LINFOCITOS DETENIDOS POR INMUNIZACION DE UN ANIMAL CON ACIDO N - ACETIL MURAMINICO O DE UN DERIVADO DE ESTE EN UN DISPOSITIVO BETA COMO UN ANTIGENO Y (II) CELULAS DE MIELONA.
ES88118876T 1987-11-13 1988-11-11 Anticuerpos monoclonales capaces de reconocer acido n-acetilneuraminico en configuracion beta. Expired - Lifetime ES2054772T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28711987 1987-11-13
JP63026848A JPH02486A (ja) 1987-11-13 1988-02-08 遊離ｎ−アセチルノイラミン酸を認識するモノクローナル抗体

Publications (1)

Publication Number Publication Date
ES2054772T3 true ES2054772T3 (es) 1994-08-16

Family

ID=26364692

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88118876T Expired - Lifetime ES2054772T3 (es) 1987-11-13 1988-11-11 Anticuerpos monoclonales capaces de reconocer acido n-acetilneuraminico en configuracion beta.

Country Status (13)

Country Link
US (1) US5158886A (es)
EP (1) EP0316818B1 (es)
JP (1) JPH02486A (es)
KR (1) KR960004855B1 (es)
AU (1) AU614553B2 (es)
CA (1) CA1336763C (es)
DE (1) DE3881344T2 (es)
ES (1) ES2054772T3 (es)
FI (1) FI90989C (es)
HU (1) HU204897B (es)
IL (1) IL88322A (es)
NO (1) NO174110C (es)
NZ (1) NZ226937A (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03242553A (ja) * 1990-02-19 1991-10-29 Mect Corp エピシアロ複合糖質を含む製剤
US7682794B2 (en) 2003-07-15 2010-03-23 The Regents Of The University Of California Methods for detecting and analyzing N-glycolylneuraminic acid (Neu5Gc) in biological materials
CN100401753C (zh) * 2004-07-20 2008-07-09 上海乐金广电电子有限公司 数码tv接收用智能天线控制系统
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
WO2017083582A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59164798A (ja) * 1983-03-09 1984-09-17 Rikagaku Kenkyusho シアル酸含有糖脂質誘導体

Also Published As

Publication number Publication date
JPH02486A (ja) 1990-01-05
EP0316818A2 (en) 1989-05-24
EP0316818B1 (en) 1993-05-26
NO174110C (no) 1994-03-16
NO885053D0 (no) 1988-11-11
DE3881344D1 (de) 1993-07-01
HUT48676A (en) 1989-06-28
NO174110B (no) 1993-12-06
FI90989C (fi) 1994-04-25
NZ226937A (en) 1991-02-26
KR960004855B1 (ko) 1996-04-16
HU204897B (en) 1992-02-28
KR890007755A (ko) 1989-07-05
CA1336763C (en) 1995-08-22
US5158886A (en) 1992-10-27
FI885169A (fi) 1989-05-14
FI885169A0 (fi) 1988-11-10
DE3881344T2 (de) 1993-09-09
AU614553B2 (en) 1991-09-05
IL88322A (en) 1994-05-30
EP0316818A3 (en) 1990-08-22
AU2498288A (en) 1989-05-18
FI90989B (fi) 1994-01-14
NO885053L (no) 1989-05-16

Similar Documents

Publication Publication Date Title
FI801342A (fi) En hybridcell-linje foer framstaellning av en komplementbindande monoklonal antikropp mot maenskliga t-celler antikroppen samt terapeutiska och diagnostiska metoder i vilka antikroppen anvaendes
ATE13198T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches t-zellenantigen, antikoerper und verfahren.
FI801343A (fi) En hybridcell-linje foer framstaellning av en monoklonal antikropp mot maenskliga hjaelpare-t-celler antikroppen samt terapeutiska och diagnostiska metoder i vilka antikroppen anvaendes
NO803658L (no) Hybridcellelinje for fremstilling av komplementfikserende monoklonalt antistoff til humane undertrykker t-celler, selve antistoffet og fremgangsmaater for dets fremstilling
ES530853A0 (es) Un metodo para separar una toxina bacteriana de una muestra biologica
NO159888C (no) Monoklonalt antistoff.
ES2054772T3 (es) Anticuerpos monoclonales capaces de reconocer acido n-acetilneuraminico en configuracion beta.
GR3029774T3 (en) Method of preparing a radioactive rhenium complex solution.
DK392387A (da) Monoklonalt antistrof til diagnostisk anvendelse og fremgangsmaade til fremstilling af et saadan antistof
ATE73350T1 (de) Verfahren zur tierischen wachstumsfoerderung.
ATE7761T1 (de) Impfstoff und herstellungsverfahren.
Vaerman et al. Communications: Identification of IgA in several mammalian species
FI803755L (fi) En hybridcell-linje foer framstaellning av en monoklonal antikropp mot en maensklig tymosytantigen antikroppen samt terapeutiska och diagnostiska metoder i vilka antikroppen anvaendes
DE59209079D1 (de) Monoklonale Antikörper gegen humane Pankreas-Inselzellen
DK162721C (da) Humane anti-rh(d) monoklonale antistoffer, antistofferne til anvendelse til passiv immunisering, anti-rh(d)-reagenser og farmaceutiske praeparater, derindeholder antistofferne, humane lymfocytafledte cellelinjer, der producerer antistofferne, samt fremgangsmaade til rh-typebestemmelse under anvendelse af antistofferne
DK0387873T3 (da) Anti-humant spermaantistof, fremstilling og anvendelse deraf
KR860006989A (ko) 인체의 심방의, 나트륨 이뇨성 펩티드에 대한 모노클론 항체
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DK69590A (da) Humane anti-rh(d) monoklonale antistoffer
EP0155172A3 (en) Anti-human lung cancer monoclonal antibodies
Dimenstein The road from cytotoxins to immunohistochemistry
ES2090331T3 (es) Ctaa 28a32, antigeno reconocido por mca 28a32.
DK329789D0 (da) Monoklonalt antistof
Boyer et al. Quantitation of the Sm nuclear antigen in tissues and activated lymphocytes
ES8401982A1 (es) "procedimiento de preparacion de globulina antilinfocitaria t".

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 316818

Country of ref document: ES